Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at BMO Capital Markets
Research analysts at BMO Capital Markets began coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) in a research report issued on Friday,Briefing.com Automated Import reports. The brokerage set a “market perform” rating and a $55.00 price target on the stock. BMO Capital Markets’ price objective points to a potential upside of 24.77% […]
More Stories
SuRo Capital (NASDAQ:SSSS) & BNY Mellon Strategic Municipal Bond Fund (NYSE:DSM) Head to Head Analysis
BNY Mellon Strategic Municipal Bond Fund (NYSE:DSM – Get Free Report) and SuRo Capital (NASDAQ:SSSS – Get Free Report) are...
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) Announces January 16th IPO
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) expects to raise $12 million in an IPO on Thursday, January 16th, IPO Scoop...
Top humanitarian official issues ceasefire appeal during visit to Gaza City
The UN Humanitarian Coordinator for the Occupied Palestinian Territory called on Sunday for an end to the war in Gaza...
Comparing AGC (OTCMKTS:ASGLY) & Sonic Healthcare (OTCMKTS:SKHHY)
AGC (OTCMKTS:ASGLY – Get Free Report) and Sonic Healthcare (OTCMKTS:SKHHY – Get Free Report) are both mid-cap industrial products companies,...
Comparing South Bow (SOBO) and Its Rivals
South Bow (NYSE:SOBO – Get Free Report) is one of 21 public companies in the “Pipelines, Except Natural Gas” industry,...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...